Robin described 2025 as a pivotal year, highlighting "the first positive results from the 2 Phase IIb studies of REZPEG in atopic dermatitis and alopecia areata," validating the company's Treg ...
Hosted on MSN
Maker of Mounjaro warns of dangerous 'chemical reactions' in knock-off versions of weight-loss drug
The maker of blockbuster weight-loss drugs Mounjaro and Zepbound has issued an urgent warning against knockoff versions of the medications over 'critical safety issues.' Pharmaceutical giant Eli Lilly ...
Complementary biochemical and structural findings reveal molecular principles underlying substrate selectivity by a model hyaluronan synthase.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results